NClip

Antitussives

3 min read

Antitussives

Key Points

  • Antitussives suppress cough reflex pathways and are used when cough is dry, nonproductive, and disruptive to rest.
  • Dextromethorphan is a non-opioid antitussive; benzonatate is a non-opioid peripheral antitussive; codeine-guaifenesin includes an opioid component.
  • Common safety risks include sedation, CNS-depressant interactions, and respiratory depression (especially with opioid-containing products or overdose).
  • Dextromethorphan misuse at high doses can cause dissociation or hallucinations.
  • Pediatric and respiratory-risk clients require stricter screening before use.

Mechanism of Action

Antitussives reduce cough by increasing the threshold for cough reflex activation:

  • Dextromethorphan depresses the cough center in the medulla and reduces cough-receptor response in the throat, trachea, and lungs.
  • Benzonatate reduces cough signaling by anesthetizing stretch receptors in the respiratory tract.
  • Codeine-guaifenesin combines central opioid cough suppression (codeine) with secretion-thinning support (guaifenesin).

Indications

  • Dry, hacking, nonproductive cough that interferes with sleep or recovery.
  • Selected infectious cough contexts when short-term suppression is clinically appropriate.
  • Codeine-guaifenesin may be used when cough suppression and mucus-loosening support are both needed.

Nursing Considerations

  • Do not use dextromethorphan products in children younger than 4 years without prescriber direction.
  • Avoid alcohol and other CNS depressants with all antitussive therapy due to additive sedation risk.
  • Use dextromethorphan cautiously in clients with respiratory disease and in those taking MAOIs.
  • Screen for misuse risk with dextromethorphan, especially when high-dose use is suspected.
  • For benzonatate:
    • swallow capsules whole; do not crush, chew, or dissolve in the mouth.
    • monitor closely for high-dose respiratory depression risk, especially in clients with baseline respiratory compromise.
    • assess concurrent opioids, benzodiazepines, and alcohol use.
  • For codeine-guaifenesin:
    • assess baseline respiratory effort before dosing.
    • use the lowest effective dose for the shortest feasible duration.
    • monitor for abuse/dependence patterns and worsening sedation.
    • use caution with respiratory disease and concurrent benzodiazepines, antidepressants, or other opioids.

Side Effects and Adverse Effects

  • Dextromethorphan: nausea, drowsiness, mild GI effects, possible rash or breathing difficulty; high doses may cause hallucinations and dissociation.
  • Benzonatate: sedation, dizziness, nausea, constipation, headache, dry mouth, nasal congestion, itching, or rash.
  • Codeine-guaifenesin: sedation, dizziness, respiratory depression, blurred vision, dry mouth, urinary retention, nausea, vomiting, and constipation.

Health Teaching

  • Use only as directed; do not exceed label or prescription dosing.
  • Avoid smoking and other airway irritants that trigger cough.
  • Avoid alcohol/CNS depressants and avoid driving or hazardous activity when drowsy.
  • Seek urgent care for slowed breathing, severe sedation, rash, hallucinations, or major mental-status change.
  • For opioid-containing antitussives, discuss safe storage and misuse prevention.

Clinical Judgment Application

Clinical Scenario

A patient with nighttime nonproductive cough requests OTC relief and reports taking a sedative-hypnotic at bedtime.

  • Recognize Cues: Sleep-disruptive cough plus concurrent CNS-depressant use.
  • Analyze Cues: Antitussive selection must minimize additive sedation and respiratory risk.
  • Prioritize Hypotheses: Primary risk is medication-related respiratory/CNS depression.
  • Generate Solutions: Screen agent options, avoid unsafe combinations, reinforce short-duration and warning signs.
  • Take Action: Recommend safer regimen pathway per prescriber/pharmacist guidance and provide interaction counseling.
  • Evaluate Outcomes: Cough burden improves without excess sedation or breathing compromise.

Graph View